Compass Therapeutics Investor Presentation Deck
CTX-009 Phase 1 Program Summary
Phase 1a: dose-escalation monotherapy study
N=45: Gastric, CRC, Other
Nine dose-escalation cohorts (0.3-17.5 mg/kg)
Four dose-expansion cohorts (7.5-15 mg/kg)
Phase 1 Results »
COMPASS
THERAPEUTICS
Phase 1b: combination study with chemotherapy
N=17: 4 arms
1. CTX-009 10.0 mg/kg + paclitaxel
2. CTX-009 10.0 mg/kg + irinotecan
3. CTX-009 12.5 mg/kg + paclitaxel
4. CTX-009 12.5 mg/kg + irinotecan
Safety: well-tolerated; MTD has not been determined
Activity: 8 PRs, 6 confirmed by RECIST in 33 advanced solid tumor patients treated
Responses as a monotherapy: colorectal and gastric
Responses in combination with chemotherapy: cholangiocarcinoma, pancreatic
Cholangio ORR= 50%; Clinical benefit rate = 75% with a median duration of response of 9.7 months
9View entire presentation